• Policy
• Phase 3 of SK Biopharm's Cenobamate is approved
• by Lee, Hye-Kyung Feb 24, 2022 05:58am

• Company
• Yuhan’s ‘Leclaza’ makes ₩4.1 billion in 6 months
• by Chon, Seung-Hyun Feb 24, 2022 05:58am

• Policy
• Generic for Revlimid was listed as the lowest price
• by Lee, Tak-Sun Feb 24, 2022 05:58am

• Policy
• Combination indication for Entresto has changed
• by Lee, Hye-Kyung Feb 24, 2022 05:58am

• Company
• It was improved by changing the targeted therapy formulation
• by Eo, Yun-Ho Feb 23, 2022 05:50am

• Policy
• Competition in full swing for the ₩100 bil Humira mkt
• by Lee, Tak-Sun Feb 23, 2022 05:50am

• Company
• Lilly-RosVivo signed a contract to transfer diabetes txs
• by Eo, Yun-Ho Feb 23, 2022 05:49am

• Policy
• Jae-Myung Lee pledges to enact Special Bio Act
• by Lee, Jeong-Hwan Feb 23, 2022 05:49am

• Opinion
• [Reporter's view]Will it be different this time?
• by Kim, Jin-Gu Feb 23, 2022 05:49am

• Policy
• Galvus generics to be reimbursed despite exclusivity period
• by Lee, Tak-Sun Feb 22, 2022 05:55am